- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
natalizumab is an approved drug (FDA (2004), EMA (2006))
Compound class: Antibody
Comment: Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a significant new focus for the development of novel anti-inflammatory therapeutics .
The design and synthesis of this antibody is described in , but the article is not open access.
View more information in the IUPHAR Pharmacology Education Project: natalizumab
1. Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP et al.. (2020)
Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Bone Marrow Transplant, [Epub ahead of print]. [PMID:32895491]
2. Léger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S, Saldanha J, Jones ST, Fritz LC, Bendig MM. (1997)
Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis.
Hum Antibodies, 8 (1): 3-16. [PMID:9265500]
3. Mackay CR. (2008)
Moving targets: cell migration inhibitors as new anti-inflammatory therapies.
Nat Immunol, 9 (9): 988-98. [PMID:18711436]
4. No authors listed. (2004)
Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Drugs R D, 5 (2): 102-7. [PMID:15293871]